wouldn't it be amazing if they were collaborating more instead of competing for market share and profits.
-
-
This Tweet is unavailable.
-
-
-
-
Perhaps because it would then be a different vaccine and need the whole approval business all over again?
-
Pfizer/BioNTech actually does have other candidates in the pipeline that may be improved.
- Show replies
New conversation -
-
-
Well Moderna might not be ready to share that proprietary info yet and, as others said, you would have to re-run at least some of the clinical trials, Phase I for sure.
Thanks. Twitter will use this to make your timeline better. UndoUndo
-
-
-
Not as straight forward as it might seem, but probably doable if we actually cared about efficiently improving health outcomes. The deal would need to limit Pfizer’s usage of the IP to Covid19 and FDA would need to ensure the “hybrid” didn’t introduce changes requiring retesting.
-
I don't know how it would work, but if it could work, it would be a big difference.
End of conversation
New conversation -
Loading seems to be taking a while.
Twitter may be over capacity or experiencing a momentary hiccup. Try again or visit Twitter Status for more information.